Compounds for treating arenavirus infections
By screening effective arenavirus GP pseudovirus inhibitors through heterocyclic compounds, the problem of limited existing treatment methods is solved, broad-spectrum inhibition and treatment of arenavirus infection is achieved, and the safety and efficacy of drugs are improved.
Patent Information
- Application Number
- CN201980080594.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-12-06
- Filing Date
- 2019-12-03
- Publication Date
- 2025-10-17
- Estimated Expiration
- 2040-02-15
AI Technical Summary
Existing treatments for arenaviruses are limited, especially for highly pathogenic arenaviruses such as Lassa virus (LASV) and LuJov virus (LUJV). Existing vaccines are unable to effectively respond to the diversity and rapid emergence of new virus strains, and there is a lack of broad-spectrum antiviral drugs to provide effective treatment and prevention measures.
By using heterocyclic compounds, especially compounds represented by structural formula I, as inhibitors of arenavirus GP pseudovirus screening, the virus is inhibited from entering cells, effective compounds are screened out and their activity against natural viruses is tested for the treatment and prevention of arenavirus infection.
It provides broad-spectrum inhibition and therapeutic effects on arenavirus infection, reduces viral load, reduces side effects, and improves the metabolic stability and safety of drugs.